Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DDY391 for Sjögren's disease
2025-524513-92-00Phase 2Authorised
- Sponsor
- Novartis
- Start
- Oct 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 26
01
Overview
Phase 2, randomised, double-blind trial in Sjögren's syndrome comparing DDY391 with Placebo (2 arms). Primary endpoints: Change from baseline in EULAR Sjögren's Syndrome Disease Activity Index score at Week 24 and Change from baseline in EULAR Sjögren's Syndrome Patient Reported Index at Week 24. Planned start Oct 2026; status: authorised.
02
Drugs
DDY391
03
Conditions
Sjögren's syndrome
Beyond the preview
Go deeper on 2025-524513-92-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-524513-92-00.